Clinical Trials

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

Phase 2 Recruiting

30 enrolled

Multiple Myeloma

NCT04933539 2026-02-27

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Multiple Myeloma

NCT04113018 2026-02-03

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

39 enrolled 16 charts

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT04430894 2026-01-29

KRDI in Transplant-Eligible MM

50 enrolled 20 charts

Multiple Myeloma

NCT02969837 2026-01-16

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

46 enrolled 10 charts

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

118 enrolled

Multiple Myeloma

NCT05789303 2025-12-22

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Recruiting

83 enrolled

Multiple Myeloma

NCT04850599 2025-12-18

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

5 enrolled

Multiple Myeloma

NCT03290950 2025-12-15

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

75 enrolled

Multiple Myeloma

NCT02302495 2025-12-08

IFM2012-03

32 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

200 enrolled

Multiple Myeloma

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

43 enrolled

Multiple Myeloma, Recurrence

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT01559935 2025-09-08

CarBiRD

74 enrolled 12 charts

Multiple Myeloma

NCT04191616 2025-09-04

SELECT

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT03314636 2025-08-08

CONPET

53 enrolled

Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01816971 2025-06-10

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

76 enrolled 12 charts

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

36 enrolled 17 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT03556332 2025-04-29

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Multiple Myeloma

NCT04263480 2025-04-04

CZAR-1

99 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms

NCT03871829 2025-03-30

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

88 enrolled 21 charts

Multiple Myeloma

NCT02405364 2025-01-27

IFM-CRd

46 enrolled

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

143 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT02203643 2024-12-05

FORTE

477 enrolled

Multiple Myeloma

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

52 enrolled

Multiple Myeloma

NCT03104842 2024-05-29

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

246 enrolled

Multiple Myeloma

NCT02891811 2024-03-29

Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

124 enrolled

Multiple Myeloma

NCT03289299 2023-12-12

ASCENT

87 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

62 enrolled 10 charts

Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

NCT03224507 2023-11-24

MASTER

123 enrolled 14 charts

Multiple Myeloma

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

45 enrolled

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

45 enrolled

Multiple Myeloma, Recurrence

NCT03673826 2023-11-01

HO147SMM

58 enrolled

Smoldering Multiple Myeloma

NCT01346787 2023-09-08

CCD

58 enrolled

Multiple Myeloma

NCT02597062 2023-08-28

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

76 enrolled 9 charts

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05909826 2023-06-18

KMM-KCd

49 enrolled

Multiple Myeloma

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Multiple Myeloma

NCT03891355 2022-09-15

FIL_KLIMT

Phase 2 Unknown

16 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02415413 2022-09-10

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

90 enrolled

Smoldering Multiple Myeloma

NCT03336073 2022-09-07

Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma

Phase 2 Unknown

199 enrolled

Multiple Myeloma

NCT05509374 2022-08-22

KMM2002

Phase 2 Unknown

33 enrolled

Multiple Myeloma

NCT03256045 2022-05-09

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

9 enrolled 12 charts

Multiple Myeloma

NCT01813227 2022-04-13

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531